Available Technology

Cannabinoids As Neuroprotectants

This technology describes the neuroprotective properties of cannabidiol(CBD), 2-[3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1yl]-5-pentyl-1,3-benzenediol. Cannabidiol is a neuroprotective cannabinoid that does not possess the psychoactive qualities which have previously hampered the development of cannabinoid-based therapeutics. Cannabidiol is an effective blood-brain barrier permeable antioxidant, that is more potent than either tocopherol or ascorbate. As reported in PNAS 95, 8268-73 (July 1998), CBD can protect neurons from both glutamate and free radical induced toxicity. It is believed that CBD may present a viable alternative for treatment of ischemia or physical traumas.
Abstract: 
This technology describes the neuroprotective properties of cannabidiol(CBD), 2-[3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1yl]-5-pentyl-1,3-benzenediol. Cannabidiol is a neuroprotective cannabinoid that does not possess the psychoactive qualities which have previously hampered the development of cannabinoid-based therapeutics. Cannabidiol is an effective blood-brain barrier permeable antioxidant, that is more potent than either tocopherol or ascorbate. As reported in PNAS 95, 8268-73 (July 1998), CBD can protect neurons from both glutamate and free radical induced toxicity. It is believed that CBD may present a viable alternative for treatment of ischemia or physical traumas. Aidan Hampson (NIMH)➽ more inventions... Julius Axelrod (NIMH)➽ more inventions... Maurizio Grimaldi (NINDS)➽ more inventions... U.S. Pat:6,630,507issued 2003-10-07 US Application No. 60/095,993 PCT Application No. PCT/US99/08769 US Application No. 09/674,028 Jennifer Wong, M.S. Email:jennifer.wong2@nih.gov Phone: 301-480-4821 E-287-1997/0 Updated:Nov 9, 2015
Inventors: 
Aidan Hampson
Patent Number: 
6,630,507issued 2003-10-07 US Application No. 60/095,993 PCT Application No. PCT/US99/08769 US Application No. 09/674,028
Internal Laboratory Ref #: 
E-287-1997/0 Updated:Nov 9, 2015
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin